Adma Biologics (ADMA) Work In Process (2017 - 2025)

Adma Biologics' Work In Process history runs 9 years deep, the most recent figure standing at $57.8 million for Q4 2025.

• Quarterly Work In Process fell 6.23% year-over-year to $57.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $57.8 million (down 6.23% YoY) and the FY2025 annual result came in at $57.8 million, down 6.23% from the prior year.
• Work In Process was $57.8 million for Q4 2025 at Adma Biologics, up from $44.5 million in the prior quarter.
• Across five years, Work In Process topped out at $62.1 million in Q1 2023 and bottomed at $43.2 million in Q2 2025.
• A 5-year average of $53.1 million and a median of $53.5 million in 2024 frame the typical range for Work In Process.
• Annual changes were most pronounced in 2021 — Work In Process soared 94.66% — and 2025, when it dropped 21.6%.
• Adma Biologics' Work In Process stood at $59.0 million in 2021, then slipped by 4.74% to $56.2 million in 2022, then declined by 11.66% to $49.6 million in 2023, then grew by 24.22% to $61.6 million in 2024, then dropped by 6.23% to $57.8 million in 2025.
• Business Quant data shows ADMA's Work In Process at $57.8 million in Q4 2025, $44.5 million in Q3 2025, and $43.2 million in Q2 2025.